Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies

NCT01056965 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01056965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01056965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
December 31, 2012
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corticobasal degeneration syndrome, frontotemporal dementia with parkinsonism linked to chromosome 17, predicted tauopathies, including, progressive nonfluent aphasia, progressive supranuclear palsy